INTRODUCTION
Chronic liver diseases (CLD) may result from viral hepatitis, alcohol and drug abuse, metabolic diseases and autoimmune attack.
Such insults trigger hepatocyte apoptosis, impairment of the endothelial barrier, recruitment of inflammatory cells, and activation of hepatic stellate cells (HSCs), ultimately resulting in the onset of liver fibrosis [1, 2] . Although liver transplantation is the only effective treatment for end-stage CLD, cell-based therapy has been proposed as a less invasive potential alternative to CLD. Several cells, including primary hepatocytes, unsorted bone marrow cells 
Primary hepatocytes
The transplantation of primary hepatocytes represents a potential cell-based therapy for liver diseases, including metabolic disorders and acute liver failure [5] . However, human hepatocytes have been shown to be unsuitable as the availability of human livers as a source of cells is limited, and it is difficult to maintain hepatocyte viability and function during cryopreservation of the liver. In addition, hepatocytes are difficult to culture in vitro [6] . Moreover, while the safe transplantation of -5% of the total recipient liver cell mass (a maximum of 1-2×10 8 hepatocytes/body weight
[kg]) has been demonstrated in human clinical trials [7] , it has been reported that replacement of at least 10% of the hepatocellular mass is needed to compensate for missing or inactive proteins in genetic inborn errors of metabolism [8] .
Unsorted bone marrow cells
The infusion of unsorted BMCs in patients with cirrhosis has been reported to be safe and feasible. Moreover, the infusion of The transplantation of mesenchymal stem cells (MSCs) represents a potentially effective therapy for chronic liver diseases. The potential of MSCs in the treatment of chronic liver disease is based on their ability to differentiate into multiple cell types including hepatocytes, their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and pre-clinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterized, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration. These trophic factors not only reduce inflammation, apoptosis, and fibrosis in damaged tissues but also stimulate angiogenesis and tissue regeneration in the impaired liver. In this review, we summarize the basic and therapeutic properties of MSCs, their therapeutic mechanisms of action, and potential transplantation routes for the treatment of chronic liver disease. We also discuss several risks associated with the use of MSCs in therapy, such as their fibrogenic potential and capacity to promote pre-existing tumor cell growth.
mobilization of CD34+ cells into the peripheral blood, can be isolated, amplified, and differentiated into hepatocyte-like cells [11] .
The infusion of hematopoietic stem cells improves serum albumin levels as well as Child-Pugh scores [12] . Although infused hematopoietic stem cells can differentiate into hepatocytes, through cell fusion or paracrine effects [13] , further studies are necessary to define the role of hematopoietic stem cell therapy in liver disease patients.
Mesenchymal stem cells (MSCs)
MSCs can be isolated by plastic adherence from adipose tissue, brain, dermis, liver, lung, peripheral blood, skeletal muscle, umbilical cords, and cord blood [14, 15] . MSCs are potentially useful therapeutic agents for the treatment of liver diseases, because of their potential to differentiate into hepatocytes, as well as their immunomodulatory properties and ability to secrete trophic factors.
These properties, putative therapeutic mechanisms, and injection routes of MSCs are discussed in detail in a later section.
Embryonic stem cells (ESCs)
ESCs, which are isolated from the inner cell mass of blastocyststage embryos, have pluripotent differentiation potentials, including the ability to differentiate into hepatocyte-like cells. However, although ESCs have been shown to improve liver function in CCl4-treated mice [3] , several issues are associated with their use, such as teratoma formation, ethical issues, and immune rejection problems [16] .
Induced pluripotent stem cells (iPSCs)
The use of iPSCs, produced from patient-specific cells, allows ethical and immune rejection-related issues to be circumvented. As trans-differentiation of MSCs into hepatocytes is rarely observed (less than 1% of the total liver mass) in animal models, recently published data suggest that the therapeutic potential of MSCs in the treatment of CLDs would be primarily based on their ability to secrete trophic factors, and their immunosuppressive effects, rather than trans-differentiation into hepatocytes [25, 26] .
PROPERTIES OF MESENCHYMAL STEM CELLS

THERAPEUTIC MECHANISMS OF MESENCHYMAL STEM CELLS IN THE TREATMENT OF CHRONIC LIVER DISEASES
Migration of mesenchymal stem cells
MSCs migrate towards damaged areas in response to homing signals. Many studies have shown that MSCs are able to migrate to injured tissues from blood, and exert therapeutic effects at these sites of injury [27] . Various factors, such as chemokines, cytokines, and growth factors, released upon injury, play roles as migratory cues for systemically or locally transplanted MSCs [28] . Specific receptors and ligands that are upregulated in injured tissues facilitate trafficking, adhesion, and infiltration of MSCs at sites of injury [27] . Moreover, these tissues provide MSCs with the appropriate microenvironment for self-renewal and maintenance of multi-potentiality [27] . Integrins, selectins, and chemokine receptors [29] expressed on MSCs play key roles in their migration across the endothelium. In addition, MSCs are passively arrested in capillaries or microvessels, including arterioles and post-capillary venules, where they interact directly with accessory cells and release a wide array of soluble growth factors and trophic cytokines [30] . 
Immunosuppressive potential of mesenchymal stem cells
MSCs can suppress immune cells, such as B-cells, T-cells, dendritic cells (DCs), and natural killer cells (NKs
Anti-oxidant activities of mesenchymal stem cells
Excessive reactive oxygen species (ROS) induces liver diseases such as liver fibrosis, cirrhosis, viral hepatitis, hepatocellular carcinoma (HCC) and others through oxidative disease [43] . Carbon tetrachloride (CCl4) and thioacetamide (TAA) are toxins used to generate liver injury in animal models [44] . These toxins stimulate ROS production, which result in hepatocyte damage through lipid peroxidation and the alkylation of proteins, nucleic acids, and lipids [44, 45] . MSCs have been shown to overcome CCL4-and TAAinduced oxidative stress in vitro and to reduce liver injury through anti-oxidant activities in vivo [44, 46] . The upregulation of ROS in CCl4-treated liver cells has been reported to be attenuated by coculturing with MSCs via an increase in superoxide dismutase (SOD) activity and the induction of AREs, which represents a cytoprotective response in the injured liver [44] . Additionally, MSCs protect hepatocytes by reducing ROS damage that is induced by TAA both in vivo and in vitro [46] .
TRANSPLANTATION ROUTE OF MESENCHYMAL STEM CELLS
MSCs communicate with other cells in the body and migrate and α-SMA but not hepatic markers [49] . Therefore, the MSC transplantation route used should be taken into consideration for enhancement of stable engraftment, and reduction of the fibrogenic effects of MSCs. Nevertheless, several issues, including those that involve the fibrogenic potential of MSCs and their ability to promote pre-existing tumor cell growth, must be carefully considered.
FUTURE PERSPECTIVES
